BioFunding Summit 2003 to Address Business Opportunities in Biosciences, Drug Development and Translational Research.Business Editors/Health/Medical Writers BIOWIRE2K BETHESDA, Md., PHOENIX & PHILADELPHIA--(BUSINESS WIRE)--Aug. 5, 2003 National Foundation for Cancer Research The National Foundation for Cancer Research was founded in 1973 as a non-profit organization under U.S. tax code 501(c)(3). Over the past 30 years, NFCR has provided more than $200 million in support of discovery-oriented basic science cancer research and cancer prevention. , International Genomics Consortium and The Scientist magazine to Host Conference The National Foundation for Cancer Research, the International Genomics Consortium and The Scientist magazine have joined forces to hold "Biofunding Summit 2003: New Frontiers in Cancer Research" October 16 - 18, 2003 in Phoenix, AZ. Targeted at researchers on the cutting edge of discovery, investors, stock analysts, venture capital groups and, biotech and pharmaceutical executives, the conference will highlight investment opportunities in the Biosciences and provide an informative working session with the world's leading scientists on the inside track to breaking developments in Cancer Research, New Therapies, Novel Treatments and Drug Development. The NFCR NFCR National Foundation for Cancer Research NFCR National Fund for Calamity Relief (India) NFCR National Flow Cytometry Resource (Los Alamos National Laboratory) will celebrate its 30th anniversary at this conference by presenting a scientific overview on developing breakthroughs in cancer research and drug development featuring some of the world's leading cancer researchers. Speakers for the Biofunding Summit Investors Forum on October, 16th include: -- Jeff Trent, Ph.D., - President, Translational Genomics Research Institute -- Dan Von Hoff, M.D. - Director, Arizona Cancer Center and the NFCR Center for New Therapies Development -- William Hazeltine Ph.D. - CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Human Genome Sciences Human Genome Sciences NASDAQ: HGSI is a biopharmaceutical corporation founded in 1992. Its stated purpose is to "discover, develop, manufacture and market innovative drugs that serve patients with unmet medical needs, with a primary focus on protein and antibody drugs. , Inc. -- Roy Parker, Ph.D. - Arizona Cancer Center -- Elizabeth Jaffee, M.D. - Johns Hopkins University Johns Hopkins University, mainly at Baltimore, Md. Johns Hopkins in 1867 had a group of his associates incorporated as the trustees of a university and a hospital, endowing each with $3.5 million. Daniel C. -- Charles Sawyers, M.D. - UCLA UCLA University of California at Los Angeles UCLA University Center for Learning Assistance (Illinois State University) UCLA University of Carrollton, TX and Lower Addison, TX -- Paul Schimmel Schimmel is a German surname and may refer to:
-- George Poste, D.V.M., Ph.D. - CEO, Health Technology Networks -- David Mallery, J.D., MBA MBA abbr. Master of Business Administration Noun 1. MBA - a master's degree in business Master in Business, Master in Business Administration - VP, International Genomics Consortium -- David Alberts, M.D. - Arizona Cancer Center "Our goal in creating the Biofunding Summit 2003 is to show the investment community that despite all the doom and gloom doom and gloom n. Gloom and doom. doom  -and-gloom adj. you hear in the marketplace, there are some very exciting business opportunities out there, especially as they relate to new research and therapy developments and opportunities in emerging markets," said Franklin C. Salisbury, Jr., president of the National Foundation for Cancer Research. "With some of the greatest scientists in basic science research on tap to highlight their research in a business setting, this should provide an excellent forum for investors seeking news and information about breaking developments." Scientific presenters on October 17th and 18th include: -- Bruce Ames, Ph.D., Co-Director, NFCR Center for Genomics and Nutrition at UC Berkeley -- Michael Blaese, M.D., Director Fund for Inherited Disease Research -- Webster Cavenee, Ph.D., Ludwig Institute for Cancer Research The Ludwig Institute for Cancer Research (LICR) is a global non-profit medical research institute that undertakes laboratory and clinical research into cancer, conducting and sponsoring its own early-phase clinical trials to investigate its discoveries. -- Esther Chang, Ph.D., Georgetown University -- Yung-Chi Cheng, Ph.D., Yale Medical School -- Curt Civin, M.D., Johns Hopkins University -- Stanley Cohen, M.D., Stanford University School of Medicine Stanford University School of Medicine is affiliated with Stanford University and is located at Stanford University Medical Center in Stanford, California, adjacent to Palo Alto and Menlo Park. -- Ivar Giaever, Ph.D., NL, Rensselaer Polytechnic Institute Rensselaer Polytechnic Institute, at Troy, N.Y.; coeducational; founded and opened 1824 as Rensselaer School; chartered 1826. It was called Rensselaer Institute from 1837 to 1861. -- Daniel Haber, M.D., Massachusetts General Hospital Massachusetts General Hospital Health care The major teaching hospital for Harvard Medical School, widely regarded as one of the best health care centers in the world -- Daniel Von Hoff, M.D., Arizona Cancer Center -- Waun Ki Hong, M.D., M.D. Anderson Cancer Center -- Kate Horwitz, Ph.D., Colorado Health Science Center -- Susan Band Horwitz, Ph.D., Albert Einstein College of Medicine -- Laurence Hurley, Ph.D., University of Arizona (body, education) University of Arizona - The University was founded in 1885 as a Land Grant institution with a three-fold mission of teaching, research and public service. -- Wayne Marasco, M.D., Ph.D., Dana Farber Institute and Director, NFCR Center for Antibody Engineering -- Larry Marnett, Ph.D., Vanderbilt University School of Medicine -- W. Graham Richards, Ph.D., University of Oxford and Director, NFCR Center for Computational Drug Discovery at Oxford -- Michael Sporn, M.D., Dartmouth Medical School Dartmouth Medical School is the medical school of Dartmouth College, in Hanover, New Hampshire. The school is closely affiliated with Dartmouth-Hitchcock Medical Center (DHMC) in neighboring Lebanon, New Hampshire. -- Bernard Weinstein, M.D., Columbia University To attend this conference or for more information, please visit the website at www.BioFundingSummit.org or call Silas Deane at (615) 244-8035. Attendance is limited, so please reserve early. Media is highly encouraged to attend and will have access to the entire proceedings. About the NFCR Since its founding in 1973, the National Foundation for Cancer Research has spent more than $200 million funding basic science cancer research and cancer education. This worldwide "laboratory without walls" assembles the intellectual power to achieve one of medicine's greatest goals: a cure for cancer. Prevention, new treatments, and a cure depend on understanding cancer's genetic origins; NFCR is dedicated to funding scientists who are discovering cancer's molecular mysteries and translating these discoveries into therapies that hold the only real hope for curing cancer. For more information, please visit NFCR's website at www.NFCR.org or call (800) 321-CURE. About the International Genomics Consortium The International Genomics Consortium is a non-profit medical research foundation established to expand upon the discoveries of Human Genome Project and other systematic sequencing efforts by combining world-class genomic research, bioinformatics, and diagnostic technologies in the fight against cancer and other complex genetic diseases. For more information, visit www.Intgen.org. About The Scientist The Scientist is an international news magazine published in print and on the Web. It reports on and analyzes the issues and events that impact the world of life scientists. The Scientist provides a unifying forum for discussion of the topics -news, research, profession and technology - that drive scientific progress. Comprehensive and topical, it serves as an ally and a guide in today's exciting and competitive research environment. For more information, visit www.The-Scientist.com. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion